Brenus Pharma Patents

Patent portfolio assigned to Brenus Pharma (verified via public assignee records). Estimated patent count: 2. French (Lyon/Issoire) clinical-stage immuno-oncology biotech; patented 'Stimulated Tumor Ghost Cells' (STC/SGC) platform, lead STC-1010 in mCRC (FDA IND accepted 2026). Company repeatedly describes the STC platform as patented; Tracxn/CBInsights indicate ~2 patent filings. CRO collaborator Transcure (humanized-mouse models) cited as a partner. No clean public list of named direct competitors or paying customers (pre-commercial).